by Elec23 | Oct 23, 2025 | News&events
We are proud to be part of Clover Biopharmaceuticals’ important achievement in advancing innovative respiratory combination vaccines. VisMederi contributed to the RSV+hMPV±PIV3 Combination Vaccines Phase I study by performing serological analyses, supporting the...
by Elec23 | Feb 12, 2025 | News&events
According to Save the Children’s data collected in the Istat 2024 study, in Italy, just 16.8% of women aged 25 to 34 with a degree in STEM subjects (science, technology, engineering, and mathematics) are employed, compared to 37% of men. In this context,...
by Elec23 | Aug 7, 2024 | News&events
VisMederi has been successfully qualified by Qualifyze for conducting activities according to GCLP (Good Clinical Laboratory Practices). Both our laboratory facilities have achieved the prestigious SILVER rating! This outstanding result once again reflects our utmost...
by Elec23 | May 10, 2024 | News&events
VisMederi and the International Vaccine Institute have formed a new partnership to accelerate vaccine development in developing countries. VisMederi, a company at the forefront of research and innovation in the life sciences and biotechnology sectors, is pleased to...
by Elec23 | Apr 16, 2024 | News&events
VisMederi Group attended the World Vaccine Congress in Washington, D.C., acknowledged as the most significant and longstanding event dedicated to the field of vaccines. This congress served as an exceptional platform for engaging with leaders across the entire vaccine...
